Figure 3 | Scientific Reports

Figure 3

From: Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations

Figure 3

ctDNA and LDH level monitoring for patient 5 with corresponding radiological findings.

(a) Patient 5’s ctDNA level fell following treatment (CheckMate 067 trial; anti-PD-1 antibody nivolumab alone versus anti-CTLA-4 antibody ipilimumab alone versus combination of the two). The CT scans also showed disease regression with (b) red arrow points to lung metastasis on day 1 of treatment and (c) the corresponding site on day 263 with no evidence of disease. PET scan performed on day 188 showed no metabolically active lesions (Fig. 3a).

Back to article page